Figure 1

THI and PYR concentrations in three pharmaceutical samples determined by the CZE-UV method_
| Preparation | Parameters | |||
|---|---|---|---|---|
| Found ± SD (μg/mL) | RSD (%), n=3 | Declared (μg/mL) | ||
| Milgamma NA (inj) | THI | 53.15 ± 0.26 | 0.49 | 50 |
| PYR | 23.01 ± 0.23 | 0.98 | 25 | |
| Diclovit (cps) | THI | 50.81 ± 1.27 | 2.50 | 50 |
| PYR | 43.18 ± 1.07 | 2.48 | 50 | |
| B-komplex Sanofi (tbl flm) | THI | 11.59 ± 0.18 | 1.56 | 10 |
| PYR | 5.52 ± 0.50 | 9.00 | 5 | |
Performance parameters of the CZE-UV method_
| Thiamine | Pyridoxine | |
|---|---|---|
| tm (min) | 7.01 | 11.02 |
| RSDtm (%), n = 6 | 0.28 | 0.76 |
| RSDarea (%), n = 6 | 2.28 | 8.60 |
| a (mAU) | 134.76 | −39.09 |
| RSDa (%), n = 6 | 2.27 | 1.33 |
| b (mAU/μg mL) | 94.77 | 36.22 |
| RSDb (%), n = 6 | 0.49 | 0.29 |
| r2 | 0.9996 | 0.9990 |
| Linear range (μg/mL) | 0.5–100 | 1–100 |
| LOD (μg/mL) | 0.08 | 0.15 |
| LOQ (μg/mL) | 0.25 | 0.50 |
| N | 7900 | 6400 |
| R | 8.81 | |